These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35128908)

  • 1. Outcomes of COVID-19 in Patients with Inflammatory Bowel Disease: Comparison with Household Members and the Role of IBD Medications.
    Sima AR; Saberzadeh-Ardestani B; Vahedi H; Fakheri H; Mansour-Ghanaei F; Maleki I; Nasseri-Moghaddam S; Vosoghinia H; Ghadir MR; Hormati A; Kasaeian A; Radmard AR; Khosravi B; Malekzadeh M; Alatab S; Sadeghi A; Aminisani N; Poustchi H; Gonoudi E; Anushiravani A; Rayatpisheh M; Colombel JF; Ungaro RC; Malekzadeh R
    Arch Iran Med; 2022 Jan; 25(1):17-25. PubMed ID: 35128908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
    Bezzio C; Armuzzi A; Furfaro F; Ardizzone S; Milla M; Carparelli S; Orlando A; Caprioli FA; Castiglione F; Viganò C; Ribaldone DG; Zingone F; Monterubbianesi R; Imperatore N; Festa S; Daperno M; Scucchi L; Ferronato A; Pastorelli L; Balestrieri P; Ricci C; Cappello M; Felice C; Fiorino G; Saibeni S;
    Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1432-1441. PubMed ID: 34694009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry.
    Agrawal M; Zhang X; Brenner EJ; Ungaro RC; Kappelman MD; Colombel JF
    J Crohns Colitis; 2021 Nov; 15(11):1877-1884. PubMed ID: 33884425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corticosteroids but not Anti-TNF Are Associated With Increased COVID-19 Complications in Patients With Inflammatory Bowel Disease.
    Long MD; Parlett L; Lewis JD; Haynes K; Adimadhyam S; Hou L; Wolfe A; Toh S; Burris J; Dorand J; Kappelman MD
    Inflamm Bowel Dis; 2024 Aug; 30(8):1345-1352. PubMed ID: 37611117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry.
    Agrawal M; Brenner EJ; Zhang X; Colombel JF; Kappelman MD; Ungaro RC; ; Gearry RB; Kalpan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Ruemmele FM; Steinwurz F; Underwood FE
    J Crohns Colitis; 2021 May; 15(5):860-863. PubMed ID: 33232456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis.
    Alrashed F; Battat R; Abdullah I; Charabaty A; Shehab M
    BMJ Open Gastroenterol; 2021 Oct; 8(1):. PubMed ID: 34725056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The natural history of COVID-19 in patients with inflammatory bowel disease: a nationwide study by the Hellenic Society for the study of IBD.
    Bamias G; Kokkotis G; Christidou A; Christodoulou DK; Delis V; Diamantopoulou G; Fessatou S; Gatopoulou A; Giouleme O; Kafritsa P; Kalantzis C; Kapsoritakis A; Karatzas P; Karmiris K; Katsanos K; Kevrekidou P; Kosmidis C; Mantaka A; Mathou N; Michalopoulos G; Michopoulos S; Papaconstantinou I; Papatheodoridis G; Polymeros D; Potamianos S; Poulopoulos G; Protopapas A; Sklavaina M; Soufleris K; Theocharis G; Theodoropoulou A; Triantafillidis JK; Triantafyllou K; Tsiolakidou G; Tsironi E; Tzouvala M; Viazis N; Xourgias V; Zacharopoulou E; Zampeli E; Mantzaris GJ
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e810-e817. PubMed ID: 34402469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19.
    Izadi Z; Brenner EJ; Mahil SK; Dand N; Yiu ZZN; Yates M; Ungaro RC; Zhang X; Agrawal M; Colombel JF; Gianfrancesco MA; Hyrich KL; Strangfeld A; Carmona L; Mateus EF; Lawson-Tovey S; Klingberg E; Cuomo G; Caprioli M; Cruz-Machado AR; Mazeda Pereira AC; Hasseli R; Pfeil A; Lorenz HM; Hoyer BF; Trupin L; Rush S; Katz P; Schmajuk G; Jacobsohn L; Seet AM; Al Emadi S; Wise L; Gilbert EL; Duarte-García A; Valenzuela-Almada MO; Isnardi CA; Quintana R; Soriano ER; Hsu TY; D'Silva KM; Sparks JA; Patel NJ; Xavier RM; Marques CDL; Kakehasi AM; Flipo RM; Claudepierre P; Cantagrel A; Goupille P; Wallace ZS; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Robinson PC; Machado PM; Griffiths CEM; Barker JN; Smith CH; Yazdany J; Kappelman MD; ;
    JAMA Netw Open; 2021 Oct; 4(10):e2129639. PubMed ID: 34661663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS).
    Nakase H; Hayashi Y; Hirayama D; Matsumoto T; Matsuura M; Iijima H; Matsuoka K; Ohmiya N; Ishihara S; Hirai F; Abukawa D; Hisamatsu T;
    J Gastroenterol; 2022 Mar; 57(3):174-184. PubMed ID: 35089397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
    Tripathi K; Godoy Brewer G; Thu Nguyen M; Singh Y; Saleh Ismail M; Sauk JS; Parian AM; Limketkai BN
    Inflamm Bowel Dis; 2022 Aug; 28(8):1265-1279. PubMed ID: 34718595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population.
    Maconi G; Bosetti C; De Monti A; Boyapati RK; Shelton E; Piazza N; Carvalhas Gabrielli AM; Lenti MV; Bezzio C; Ricci C; Greco S; Romeo S; Giangregorio F; Gridavilla D; Tagliani F; Massari A; Pastorelli L; Di Sabatino A; Saibeni S; Alicante S; Ferretti F; Rizzardini G; Galli M; Ardizzone S
    Dig Liver Dis; 2021 Mar; 53(3):263-270. PubMed ID: 33483259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease.
    Wetwittayakhlang P; Albader F; Golovics PA; Hahn GD; Bessissow T; Bitton A; Afif W; Wild G; Lakatos PL
    Can J Gastroenterol Hepatol; 2021; 2021():7591141. PubMed ID: 34858891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases.
    Brenner EJ; Pigneur B; Focht G; Zhang X; Ungaro RC; Colombel JF; Turner D; Kappelman MD; Ruemmele FM
    Clin Gastroenterol Hepatol; 2021 Feb; 19(2):394-396.e5. PubMed ID: 33059040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of adverse outcomes in inflammatory bowel disease patients infected with SARS-CoV-2: a systematic review and meta-analysis.
    Chen L; Hu K; Cheng C; Hu Q; Zhang L; An T; Guo Y; Chen S; Duan G
    Int J Colorectal Dis; 2022 Nov; 37(11):2277-2289. PubMed ID: 36271206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of inflammatory bowel disease and related medications on COVID-19 incidence, disease severity, and outcome: the Israeli experience.
    Richter V; Bermont A; Cohen DL; Broide E; Shirin H
    Eur J Gastroenterol Hepatol; 2022 Mar; 34(3):267-273. PubMed ID: 34191758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory Bowel Disease Management in a Romanian Tertiary Gastroenterology Center: Challenges of the COVID-19 Pandemic.
    Vadan R; Iacob R; Costache R; Stroie T; Saizu IA; Iacob S; Gheorghe L; Diculescu M; Gheorghe C
    J Gastrointestin Liver Dis; 2020 Dec; 29(4):549-553. PubMed ID: 33331349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study.
    Meyer A; Semenzato L; Zureik M; Weill A; Carbonnel F; Dray-Spira R
    Aliment Pharmacol Ther; 2021 Jul; 54(2):160-166. PubMed ID: 34110040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neither inflammatory bowel disease nor immunosuppressants are associated with an increased risk of severe COVID-19: an observational Dutch cohort study.
    Gilissen LPL; Heinen SGH; Rijpma-Jacobs L; Schoon E; Schreuder RM; Wensing AM; van der Ende-van Loon MCM; Bloemen JG; Stapelbroek JM; Stronkhorst A
    Clin Exp Med; 2022 Aug; 22(3):465-476. PubMed ID: 34542781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Immunotherapies on SARS-CoV-2-Infections and Other Respiratory Tract Infections during the COVID-19 Winter Season in IBD Patients.
    Waggershauser CH; Tillack-Schreiber C; Weyh P; Alt E; Siegmund T; Berchthold-Benchieb C; Szokodi D; Schnitzler F; Ochsenkühn T
    Can J Gastroenterol Hepatol; 2022; 2022():3469789. PubMed ID: 36060521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of biologics in inflammatory bowel disease patients with COVID-19.
    Weissman S; Aziz M; Smith WL; Elias S; Swaminath A; Feuerstein JD
    Int J Colorectal Dis; 2021 Sep; 36(9):2051-2055. PubMed ID: 34131784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.